-
-
subtotal : ₹ 00.00
-
Thermo Fisher's Jane Li champions the pivotal role of diagnostics in oncology, where time is a precious commodity. Their Ion Torrent Genexus System, with a swift 24-hour turnaround, leads the charge in next-gen sequencing (NGS) solutions for companion diagnostic (CDx) development.
In a landscape where NGS testing traditionally takes weeks, Thermo Fisher's rapid results offer a lifeline. Their pioneering Oncomine Dx Target Test, with FDA approval since 2019, sets the standard with simultaneous evaluation of 23 genes linked to non-small cell lung cancer.
Li emphasizes Thermo Fisher's technological edge, notably in tissue-saving NGS. Their latest offering, the Ion Torrent Genexus System, revolutionizes turnaround time for both tissue and liquid biopsies, driving CDx innovation forward.
Beyond NGS, Thermo Fisher explores CDx diversity, from traditional Sanger sequencing to protein analysis. Their robust regulatory journey, spanning the FDA and PMDA approvals, underscores their commitment to advancing CDx accessibility and efficacy.
As the CDx landscape evolves, Thermo Fisher stands poised at the forefront, shaping the future of precision medicine. With relentless innovation and unwavering dedication, they continue to redefine what's possible in oncology diagnostics.
